Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by themagicboxon Oct 25, 2019 3:11pm

95 Views

Post# 30270855

RE:RE:RE:RE:RE:RE:RE:Delay in Phase IIb

You're either an idiot or a lia (perhaps both). No source and no history of posts. Obviosuly trying to stir rumors to buy in at a lower SP... can spot peopl like you a mile away. lol

HailMary wrote: I just don't see how they can. It's taken six months to get only 2/3rds filled. The pre-screening alone can take four weeks or longer. So to find 120 more patients, four weeks pre-screen, six-weeks testing, than analyze and relaease the date

How could they possible do this during this quarter. And you call me an idiot?? What's wrong with you

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide